{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T09:25:07Z","timestamp":1785835507939,"version":"3.56.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1124\/jpet.119.264069","type":"journal-article","created":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T22:45:53Z","timestamp":1586299553000},"page":"200-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Extending the Specificity of DRL 72-s Behavior for Screening Antidepressant-Like Effects of Glutamatergic Clinically Validated Anxiolytic or Antidepressant Drugs in Rats"],"prefix":"10.1016","volume":"374","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8103-4306","authenticated-orcid":false,"given":"Gerard J.","family":"Marek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allyson A.","family":"Salek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.119.264069_bib1","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00213-009-1484-9","article-title":"Modeling \u201cpsychosis\u201d in vitro by inducing disordered neuronal network activity in cortical brain slices","volume":"206","author":"Aghajanian","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.119.264069_bib2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejphar.2008.11.018","article-title":"Modulation of group II metabotropic glutamate receptor (mGlu2) elicits common changes in rat and mice sleep-wake architecture","volume":"603","author":"Ahnaou","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.119.264069_bib3","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1124\/jpet.108.143370","volume":"327","author":"Ardayfio","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.264069_bib4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0304-3940(97)00442-4","article-title":"In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats","volume":"229","author":"Battaglia","year":"1997","journal-title":"Neurosci Lett"},{"key":"10.1124\/jpet.119.264069_bib5","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1124\/mol.107.035170","article-title":"A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis","volume":"72","author":"Benneyworth","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.119.264069_bib6","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol Psychiatry"},{"key":"10.1124\/jpet.119.264069_bib7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejphar.2008.06.089","article-title":"Behavioral characterization of the mGlu group II\/III receptor antagonist, LY-341495, in animal models of anxiety and depression","volume":"592","author":"Bespalov","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.119.264069_bib8","doi-asserted-by":"crossref","unstructured":"Caddy C, Amit BH, McCloud TL, Rendell JM, Furukawa TA, McShane R, Hawton K, Cipriani A (2015) Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev :CD011612","DOI":"10.1002\/14651858.CD011612.pub2"},{"key":"10.1124\/jpet.119.264069_bib9","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1046\/j.1471-4159.2000.0751147.x","article-title":"The potent, selective mGlu2\/3 receptor agonist LY379268 increases extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindole-3-acetic acid in the medial prefrontal cortex of the freely moving rat","volume":"75","author":"Cartmell","year":"2000","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.119.264069_bib10","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0028-3908(01)00034-X","article-title":"Acute increases in monoamine release in the rat prefrontal cortex by the mGlu2\/3 agonist LY379268 are similar in profile to risperidone, not locally mediated, and can be elicited in the presence of uptake blockade","volume":"40","author":"Cartmell","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.119.264069_bib11","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.tips.2017.03.008","article-title":"mGlu2\/3 receptor antagonists as novel antidepressants","volume":"38","author":"Chaki","year":"2017","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/jpet.119.264069_bib12","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.neuron.2011.01.020","article-title":"Impulsivity, compulsivity, and top-down cognitive control","volume":"69","author":"Dalley","year":"2011","journal-title":"Neuron"},{"key":"10.1124\/jpet.119.264069_bib13","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial","volume":"76","author":"Daly","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1124\/jpet.119.264069_bib14","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/j.neuropharm.2012.01.010","article-title":"Heterocomplex formation of 5-HT2A-mGlu2 and its relevance for cellular signaling cascades","volume":"62","author":"Delille","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.119.264069_bib15","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1038\/sj.npp.1301531","article-title":"Efficacy and tolerability of an mGlu2\/3 agonist in the treatment of generalized anxiety disorder","volume":"33","author":"Dunayevich","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.119.264069_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev.neuro.24.1.31","article-title":"The role and regulation of adenosine in the central nervous system","volume":"24","author":"Dunwiddie","year":"2001","journal-title":"Annu Rev Neurosci"},{"key":"10.1124\/jpet.119.264069_bib17","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m12928","article-title":"A phase 2, randomized, double-blind, placebo-controlled study of adjunctive pimavanserin in patients with major depressive disorder and an inadequate response to therapy (CLARITY)","volume":"80","author":"Fava","year":"2019","journal-title":"J Clin Psychiatry"},{"key":"10.1124\/jpet.119.264069_bib18","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1)","volume":"22","author":"Fedgchin","year":"2019","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1124\/jpet.119.264069_bib19","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0091-3057(02)00843-2","article-title":"The selective group mGlu2\/3 receptor agonist LY379268 suppresses REM sleep and fast EEG in the rat","volume":"73","author":"Feinberg","year":"2002","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.119.264069_bib20","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1124\/jpet.110.172957","volume":"336","author":"Fell","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.264069_bib21","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/026988110101500203","article-title":"Interactions between LY354740, a group II metabotropic agonist and the GABA(A)-benzodiazepine receptor complex in the rat elevated plus-maze","volume":"15","author":"Ferris","year":"2001","journal-title":"J Psychopharmacol"},{"key":"10.1124\/jpet.119.264069_bib22","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0091-3057(02)00844-4","article-title":"Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors","volume":"73","author":"Gewirtz","year":"2002","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.119.264069_bib23","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0893-133X(00)00136-6","article-title":"Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors","volume":"23","author":"Gewirtz","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.119.264069_bib24","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s00213-003-1444-8","article-title":"Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans","volume":"168","author":"Grillon","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.119.264069_bib25","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/FBP.0000000000000014","article-title":"Ketamine, but not MK-801, produces antidepressant-like effects in rats responding on a differential-reinforcement-of-low-rate operant schedule","volume":"25","author":"Hillhouse","year":"2014","journal-title":"Behav Pharmacol"},{"key":"10.1124\/jpet.119.264069_bib26","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.brainres.2005.02.032","article-title":"AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist","volume":"1042","author":"Karasawa","year":"2005","journal-title":"Brain Res"},{"key":"10.1124\/jpet.119.264069_bib27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.neulet.2003.10.040","article-title":"Adenosine administration produces an antidepressant-like effect in mice: evidence for the involvement of A1 and A2A receptors","volume":"355","author":"Kaster","year":"2004","journal-title":"Neurosci Lett"},{"key":"10.1124\/jpet.119.264069_bib28","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s00213-004-2025-1","article-title":"Effects of a metabotropic glutamate(2\/3) receptor agonist (LY544344\/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results","volume":"179","author":"Kellner","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.119.264069_bib29","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/S0028-3908(99)00066-0","article-title":"Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models","volume":"38","author":"K\u0142odzi\u0144ska","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.119.264069_bib30","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s00213-004-2098-x","article-title":"Anxiolytic-like activity of the mGLU2\/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice","volume":"179","author":"Linden","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.119.264069_bib31","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1124\/jpet.112.191718","article-title":"Activation of adenosine1 receptors induces antidepressant-like, anti-impulsive effects on differential reinforcement of low-rate 72-s behavior in rats","volume":"341","author":"Marek","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.264069_bib32","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/7854_2017_480","article-title":"Interactions of hallucinogens with the glutamatergic system: permissive network effects mediated through cortical layer V pyramidal neurons","volume":"36","author":"Marek","year":"2018","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1124\/jpet.119.264069_bib33","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S0006-3223(98)00036-5","article-title":"The electrophysiology of prefrontal serotonin systems: therapeutic implications for mood and psychosis","volume":"44","author":"Marek","year":"1998","journal-title":"Biol Psychiatry"},{"key":"10.1124\/jpet.119.264069_bib34","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1124\/jpet.115.229922","article-title":"The utility of impulsive bias and altered decision making as predictors of drug efficacy and target selection: rethinking behavioral screening for antidepressant drugs","volume":"356","author":"Marek","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.264069_bib35","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1038\/sj.npp.1300762","article-title":"The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine","volume":"30","author":"Marek","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.119.264069_bib36","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0306-4522(01)00199-3","article-title":"A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex","volume":"105","author":"Marek","year":"2001","journal-title":"Neuroscience"},{"key":"10.1124\/jpet.119.264069_bib37","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0022-3565(24)35262-0","article-title":"Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex","volume":"292","author":"Marek","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.264069_bib38","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/sj.mp.4002005","article-title":"Group-II metabotropic glutamate receptor ligands as adjunctive drugs in the treatment of depression: a new strategy to shorten the latency of antidepressant medication?","volume":"12","author":"Matrisciano","year":"2007","journal-title":"Mol Psychiatry"},{"key":"10.1124\/jpet.119.264069_bib39","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/j.1471-4159.2005.03141.x","article-title":"Metabotropic glutamate receptors and neuroadaptation to antidepressants: imipramine-induced down-regulation of beta-adrenergic receptors in mice treated with metabotropic glutamate 2\/3 receptor ligands","volume":"93","author":"Matrisciano","year":"2005","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.119.264069_bib40","doi-asserted-by":"crossref","first-page":"736439","DOI":"10.1155\/2013\/736439","article-title":"The mGlu2\/3 receptor agonists LY354740 and LY379268 differentially regulate restraint-stress-induced expression of c-Fos in rat cerebral cortex","volume":"2013","author":"Menezes","year":"2013","journal-title":"Neurosci J"},{"issue":"Suppl 1","key":"10.1124\/jpet.119.264069_bib41","first-page":"257","article-title":"Clinical studies with mGlu2\/3 receptor agonists: LY354740 compared with placebo in patients with generalized anxiety disorder","volume":"49","author":"Michelson","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.119.264069_bib42","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1021\/jm9606756","volume":"40","author":"Monn","year":"1997","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.119.264069_bib43","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev-pharmtox-011613-135950","article-title":"Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds","volume":"54","author":"Niciu","year":"2014","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/jpet.119.264069_bib44","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1124\/jpet.110.170506","article-title":"Effects of a positive allosteric modulator of group II metabotropic glutamate receptors, LY487379, on cognitive flexibility and impulsive-like responding in rats","volume":"335","author":"Nikiforuk","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.264069_bib45","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.neubiorev.2005.03.018","article-title":"Antidepressant effects assessed using behavior maintained under a differential-reinforcement-of-low-rate (DRL) operant schedule","volume":"29","author":"O\u2019Donnell","year":"2005","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1124\/jpet.119.264069_bib46","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00213-010-1978-5","article-title":"On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039","volume":"212","author":"Pa\u0142ucha-Poniewiera","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.119.264069_bib47","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am J Psychiatry"},{"key":"10.1124\/jpet.119.264069_bib48","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1124\/jpet.105.091926","article-title":"Improved bioavailability of the mGlu2\/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344","volume":"316","author":"Rorick-Kehn","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.264069_bib49","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0022-3565(24)29296-X","article-title":"Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system","volume":"299","author":"Schoepp","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.264069_bib50","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/1025389031000146773","article-title":"LY354740, an mGlu2\/3 receptor agonist as a novel approach to treat anxiety\/stress","volume":"6","author":"Schoepp","year":"2003","journal-title":"Stress"},{"key":"10.1124\/jpet.119.264069_bib51","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0014-2999(96)00021-0","article-title":"Effects of N6-cyclopentyladenosine and caffeine on sleep regulation in the rat","volume":"300","author":"Schwierin","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.119.264069_bib52","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S0028-3908(99)00215-4","article-title":"LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats","volume":"39","author":"Shekhar","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.119.264069_bib53","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0306-4522(01)00170-1","article-title":"Adenosine preferentially suppresses serotonin2A receptor-enhanced excitatory postsynaptic currents in layer V neurons of the rat medial prefrontal cortex","volume":"105","author":"Stutzmann","year":"2001","journal-title":"Neuroscience"},{"key":"10.1124\/jpet.119.264069_bib54","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0091-3057(02)00850-X","article-title":"The anxiolytic action of mGlu2\/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam","volume":"73","author":"Tizzano","year":"2002","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.119.264069_bib55","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/ddr.20144","article-title":"Antagonism of metabotropic glutamate group II receptors in the potential treatment of neurological and neuropsychiatric disorders","volume":"67","author":"Witkin","year":"2006","journal-title":"Drug Dev Res"},{"key":"10.1124\/jpet.119.264069_bib56","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2174\/187152707780363302","article-title":"Metabotropic glutamate receptors in the control of mood disorders","volume":"6","author":"Witkin","year":"2007","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1124\/jpet.119.264069_bib57","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1124\/jpet.116.238121","volume":"361","author":"Witkin","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.264069_bib58","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1124\/jpet.116.233627","article-title":"The rapidly acting antidepressant ketamine and the mGlu2\/3 receptor antagonist LY341495 rapidly engage dopaminergic mood circuits","volume":"358","author":"Witkin","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.264069_bib59","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.neuropharm.2012.01.019","article-title":"CNS distribution of metabotropic glutamate 2 and 3 receptors: transgenic mice and [3H]LY459477 autoradiography","volume":"66","author":"Wright","year":"2013","journal-title":"Neuropharmacology"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524257840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524257840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.119.264069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:54:36Z","timestamp":1739973276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524257840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0022356524257840"],"URL":"https:\/\/doi.org\/10.1124\/jpet.119.264069","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extending the Specificity of DRL 72-s Behavior for Screening Antidepressant-Like Effects of Glutamatergic Clinically Validated Anxiolytic or Antidepressant Drugs in Rats","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.119.264069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}